Abstract
(Am J Obstet Gynecol. 2017;216(3):204–205) This editorial advocates for the continued collective effort in perinatal medicine to employ principles of nanomedicine to improve maternal and fetal care. Nanomedicine may be able to increase the safety and efficacy of a drug by manipulating physical and chemical properties of the particles (such as size and surface chemistry) to vector it preferentially to the affected tissue, minimizing fetal exposure and combating risks associated with systemic drug toxicities to the mother and the developing fetus. Such targeted delivery of drugs to the maternal organs could revolutionize the treatment of high-risk patients for conditions such as growth abnormalities and preterm labor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
